2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

201. Granulocytes, Monocytes, and Macrophages: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Bioinformatics, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Diseases, Bone Marrow Failure Syndromes, Immunology, Autoimmune Disorders, Immunodeficiency, Neutropenia, White Blood Cell Disorders, Infectious Diseases, Viral, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, B Cell Lymphoma, T Cell Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Pediatric, Pregnant
PAPER

4721 Delta opioid receptor (DOR) inhibition drives both proenkephalin (PENK) gene expression and met-enkephalin (mENK) protein in tumor-derived myeloid-derived suppressor cells (tMDSC) and bone marrow-derived macrophage subtype 2 (BMDM2): Implications for modulation of immune suppression in cancer and autoimmune disease.

Taekyoung Kwak, PhD, Ruihua A. Chen, PhD2, Maya A. Jerald, DVM3, Edward A. Garcia, B.S.4, Arjun Jayakrishnan5, Tiffany Razabdouski, B.S.6, Erika Adriana Eksioglu, PhD7, Michael Turner, PhD8, Krit Ritthipichai, PhD9, James A. Bianco, MD10
1 TuHURA Biosciences, Tampa, Florida, United States
2 TuHURA Biosciences, Tampa, Florida, United States
3 TuHURA Biosciences, Tampa, Florida, United States
4 TuHURA Biosciences, Tampa, Florida, United States
5 TuHURA Biosciences, Tampa, Florida, United States
6 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
7 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
8 TuHURA Biosciences, Tampa, Florida, United States
9 TuHURA Biosciences, Tampa, Florida, United States
10 TuHURA Biosciences, Tampa, Florida, United States

Enkephalin production is a natural response to inflammation, notably chronic inflammation. These endogenous opioid peptides preferentially bind the DOR and are secreted by regulatory T-cells (Tregs) to naturally resolve inflammation. They are generated from the precursor protein proenkephalin, encoded by the Penk gene. We previously reported the presence of DORs on myeloid cells, including tMDSCs and BMDM2; interrupting DOR signaling with a selective DOR antagonist reprograms the immunosuppressive function of these cells (Cheng et al. (2025) Blood, 146(Suppl 1): 622 and Ritthipichai et al. (2025) Blood, 146(Suppl 1): 1201). We examined whether enkephalins may exert their anti-inflammatory effects by modulating immunosuppressive properties of tMDSCs and BMDM2 via DOR-coupled Penk gene expression. The presence of the Penk gene has not previously been reported in these cells. In this present study, we examined the presence of proenkephalin at the gene and protein level and investigated the modulatory effect of endogenous enkephalin on the immunosuppression of tMDSCs and BMDM2 in an autocrine manner.

tMDSCs were enriched from the tumor tissues of 4T1 mammary tumor-bearing mice with Gr-1+ magnetic bead selection. Gr-1+ cells were treated with a DOR antagonist (HURA-009), a DOR agonist (ADL5859), or DMSO for 4 hours and assessed for MDSC immunophenotype and DOR expression by flow cytometry. Total RNA isolated from these cells was subjected to detection of the Penk gene by qRT-PCR. BMDMs were generated from BALB/c murine bone marrow cells cultured with M-CSF for 7 days. The cells were further polarized into M1 with LPS and IFN-γ for 24 hours, while M2 were polarized with IL-4 and IL-13 for 48 hours. The cells were treated with HURA-009, ADL5859, or DMSO throughout the M1 and M2 generation process. Total RNA was isolated from the cells and assessed for Penk expression by qRT-PCR. Proenkephalin protein (PENK) was assessed in total cell lysate using western blot. 

More than 90% of Gr-1+ isolated cells displayed an MDSC immunophenotype, with approximately 80% DOR expression. The Penk gene was up-regulated in tMDSCs treated with HURA-009, but down-regulated with ADL5859 compared to DMSO (relative fold change compared to DMSO - Penk: HURA-009, 1.5 to 3.19; ADL5859, 0.69 to 1.3).  Penk gene up-regulation was noted in HURA-009-treated BMDM2, while gene down-regulation was shown in ADL5859-treated BMDM2 (relative fold change compared to DMSO - Penk: HURA-009, 1.13 to 1.5; ADL5859, 0.63 to 0.75). DOR activation with ADL5859 was associated with decreased Penk gene expression, suggesting a negative-feedback response that attenuates the enkephalin–DOR signaling axis. Conversely, DOR inhibition with HURA-009 was associated with increased Penk gene expression, consistent with a compensatory up-regulation of the enkephalin autocrine loop in response to reduced enkephalin-DOR signaling.

BMDM2 exhibited higher Penk gene and protein levels relative to BMDM1 and BMDM0. Recent transcriptomic studies have shown that PENK expression is strongly associated with FOXP3 expression in FOXP3+ regulatory T-cells (Tregs), which secrete enkephalins within local tissues to resolve inflammation. A positive correlation between PENK expression and immunosuppressive cells suggests a role for enkephalin in anti-inflammatory function in these cell types.

Ongoing studies aim to elucidate the effect of DOR signaling on enkephalin modulation and its regulation of inflammatory gene expression and suppressive functions, particularly in MDSCs, BMDM2, and Tregs. A deeper understanding of this enkephalin–DOR axis regulation may present a novel approach to enhance antitumor immunity or restore immune tolerance in autoimmune diseases.

Taekyoung Kwak, PhD: TuHura Biosciences - Current holder of stock options in a privately-held company; TuHura Biosciences - Research Funding; TuHura Biosciences - Current Employment